6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)

T.Hamaguchi; T.Yoshino; A.Ohtsu; K.Yamazaki; Y.Shimada; K.Kato; H.Yasui; N.Boku

首页> 外文期刊>European Journal of Cancer Supplements >6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)

【24h】

6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)

机译：6063对日本转移性结直肠癌（mCRC）患者（pts）一线舒尼替尼（SU）联合修饰的FOLFOX6（mFOLFOX6）的I期研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
T.Hamaguchi; T.Yoshino; A.Ohtsu; K.Yamazaki; Y.Shimada; K.Kato; H.Yasui; N.Boku;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 698 PUBLICATION Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with metastatic colorectal cancer (MCRC): comparison with published Western data [J] . European Journal of Cancer Supplements . 2005,第2期

机译：698出版物卡培他滨（X）作为日本一线治疗转移性结直肠癌（MCRC）患者的一线治疗的II期研究的有效性和安全性：与已发表的西方数据进行比较
2. Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): the CECOG/CORE1.2.001 trial [J] . I. Koza Sr., F. Wrba, D. Vrbanec, Memo - Magazine of European medical oncology . 2009,第3期

机译：一线接受FOLFOX6 +西妥昔单抗（FX + C）或FOLFIRI +西妥昔单抗（FF + C）治疗的转移性结直肠癌（mCRC）患者（pts）的KRAS状态与临床结局的相关性：CECOG / CORE1.2.001试验
3. Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-na?ve colorectal cancer [J] . YoshinoT., YamazakiK., HamaguchiT., Anticancer Research: International Journal of Cancer Research and Treatment . 2012,第3期

机译：舒尼替尼联合修饰的FOLFOX6在日本初治大肠癌患者中的I期研究
4. Single Cell Genomic Profiling of Circulating Tumor Cells (CTCs) from Metastatic Colorectal Cancer (mCRC) Identify Tumor Heterogeneity and Rare Somatic Driver Alterations [C] . Stephanie Greene, Angel Rodriguez, Jerry Lee, International Molecular Medicine Tri-Conference. . 2016

机译：转移结直肠癌（MCRC）的循环肿瘤细胞（CTC）的单细胞基因组分析识别肿瘤异质性和稀有躯体驾驶员改变
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. 5-Fluorouracil leucovorin and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study [O] . J Randolph Hecht, Edith P Mitchell, Takayuki Yoshino, 2015

机译：5-氟尿嘧啶亚叶酸钙和奥沙利铂（mFOLFOX6）加舒尼替尼或贝伐单抗作为转移性结直肠癌的一线治疗：IIb期随机研究
7. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer [O] . Elez, Elena E., Hendlisz, Alain, Delaunoit, Thierry, 2016

机译：尼妥珠单抗联合改良的FOLFOX6作为局部晚期或转移性结直肠癌患者的一线治疗的II期研究

6063 Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)

著录项

相似文献

相关主题

期刊订阅